Resources | National Pharmaceutical Council

Showing 2056 Results

NPC Submits Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses

NPC Submits Comments on the International Pricing Index Model for Medicare Part B Drugs

NPC Submits Comments on HHS RFI Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP

NPC Submits Comments on HHS Request for Information on Blueprint to Lower Drug Prices and Out-of-Pocket Costs

NPC Submits Comments to Food and Drug Administration on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

A Research-First Approach Toward Putting American Patients First

NPC Submits Comments on CMS Request for Information on New Direction for Innovation Center

NPC Submits Comments to ISPOR on Special Task Force Initiative on US Value Assessment Frameworks Draft Report

NPC Submits Comments to the FDA on Draft Guidance on Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities

NPC Comments on Proposed Updates to ICER’s Value Assessment Framework

Health Spend Management

Faced with limited health care budgets, decision-makers must make trade-offs about how they spend their health care dollars. Utilizing sound data can help decision-makers avoid unintended…

A Look Back at 2016

NPC Testimony on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Framework

Thinking Differently About How We Assess Health Value

NPC Comments on Revised PCORI Methodology Standards

NPC Comments on AMCP Format for Formulary Submission Version 4.0

The Importance of Evidence, Value, Access and Innovation in 2016

NPC Comments on ICER Value Assessment Framework

NPC Comments on ASCO Framework

Offscreen menu

Filter by:

Topic

Resource Type

Audience